Positions

Overview

  • Introduction:

    I’m honored to be an Assistant Professor at the University of Alabama at Birmingham (UAB) and the Birmingham VA Medical Center (BVAMC) since July 2021. I look forward to a career of clinical care, research, and educational endeavors, as I seek to improve the lives of older adults with cancer and patients with gastrointestinal (GI) malignancy.

    Clinical Interests & Research:

    I long been drawn to the field of geriatric oncology, and I'm truly humbled to work with older adults with cancer. Under the mentorship of Dr. Grant Williams, I have worked to assess the prevalence and potential problems of polypharmacy in older adults with gastrointestinal malignancy. As a member of the UAB Cancer and Aging Program, I look forward to providing personalized care for older adults by seeking to incorporate the geriatric assessment into routine oncologic practice.

    Additionally, I’m truly honored to work with patients with GI malignancy, and I have a particular focus in upper GI, or gastroesophageal, malignancy. The field of GI oncology continues to grow, as new trials and therapeutics are constantly evolving and advancing cancer therapy. I look forward to bringing new treatments and providing dedicated care for our wonderful patients in the city of Birmingham and the state of Alabama.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.  Cancer Medicine.  12:3488-3498. 2023
    2022 Differences in Pretreatment Frailty Across Gastrointestinal Cancers in Older Adults: Results from the Cancer and Aging Resilience Evaluation Registry.  Jco Oncology Practice.  18:E1796-E1806. 2022
    2022 Geriatric Assessment Predictors of 1-Year Mortality in Older Adults With GI Malignancies: A Survival Tree Analysis.  JCO Clinical Cancer Informatics.  6:e2200065. 2022
    2022 Racial disparities in frailty and geriatric assessment impairments in older adults with cancer in the Deep South: Results from the CARE Registry.  Cancer.  128:2313-2319. 2022
    2022 The association of polypharmacy with functional status impairments, frailty, and health-related quality of life in older adults with gastrointestinal malignancy - Results from the Cancer and Aging Resilience Evaluation (CARE) registry.  Journal of Geriatric Oncology.  13:624-628. 2022
    2022 The Evolution of Geriatric Oncology and Geriatric Assessment over the Past Decade.  Seminars in Radiation Oncology.  32:98-108. 2022
    2022 Chemotherapy dosing in older adults with cancer: One size does NOT fit all.  Journal of Geriatric Oncology.  2022
    2020 Potential main group amine borane-based chemical hydrogen storage molecular systems.  Computational and Theoretical Chemistry.  1189:112953. 2020
    2020 Is the lack of evidence in older adults with cancer compromising safety?.  Expert Opinion on Drug Safety.  19:1059-1061. 2020
    2018 Imitating the great imitator: The intersection of sarcoidosis and hodgkin’s lymphoma a report of two cases 2018
    2017 Indelible Marks: The Practice of Humanity in the Art of Medicine..  Journal of the American Geriatrics Society.  65:2740-2741. 2017
    2015 Yeast phenomics: An experimental approach for modeling gene interaction networks that buffer disease.  Genes.  6:24-45. 2015

    Principal Investigator On

    Investigator On

  • Private Grant  awarded by IPSEN BIOSCIENCES INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by FREENOME
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by ERASCA INC
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by HUTCHISON MEDIPHARMA LIMITED
  • Private Grant  awarded by GRITSTONE BIO
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by IPSEN BIOPHARMACEUTICALS, INC.
  • Private Grant  awarded by IPSEN BIOPHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by HUTCHISON MEDIPHARMA LIMITED
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by BEXION PHARMACEUTICALS
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by CARDIFF ONCOLOGY, INC.
  • Private Grant  awarded by MINNEAMRITA THERAPEUTICS, LLC ^
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • UAB22101: Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in patients with High-risk Hepatocellular Carcinoma  awarded by ACADEMIC AND COMMUNITY CANCER RESEARCH UNITED
  • XUAB 2296: A Phase II study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab  awarded by ACADEMIC AND COMMUNITY CANCER RESEARCH UNITED

    • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2015
  • Bachelor of Science or Mathematics in Chemical Engineering, University of Alabama 2011

    • Full Name

  • Darryl Outlaw